LactigaLogo.png
Lactiga Continues to Build a Substantial Global Biologics Patent Portfolio
20 juil. 2021 09h00 HE | Lactiga, Inc
PRINCETON, N.J., July 20, 2021 (GLOBE NEWSWIRE) -- Lactiga, Inc. (“Lactiga”), a biotherapeutics company advancing anti-infective biologics to prevent mucosal infections in immunodeficient patients,...
Inotiv_Logo_CMYK.png
Inotiv Acquires Laboratory Instrumentation for Discovery and Development of Novel Therapies
15 juil. 2021 08h33 HE | Inotiv, Inc.
WEST LAFAYETTE, Ind., July 15, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and...
ProgenityLogo.jpg
Progenity Announces Appointment of Surbhi Sarna to its Board of Directors
30 juin 2021 07h30 HE | Progenity, Inc.
SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced the appointment of Surbhi Sarna to its board of directors effective July...
ProgenityLogo.jpg
Progenity to Participate in the Raymond James 2021 Human Health Innovation Conference
15 juin 2021 07h30 HE | Progenity, Inc.
SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced that Harry Stylli, PhD, CEO, chairman of the board, and co-founder...
K_Swart Headshot
Kenneth Swart, Ph.D., Joins Inotiv as Vice President, Bioanalytical Sciences to Drive Growth of Expanding Laboratory Solutions Offerings
11 mai 2021 16h05 HE | Inotiv, Inc.
WEST LAFAYETTE, Ind., May 11, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and...
Qu Biologics.png
Qu Biologics Receives Funding for COVID-19 Prevention/Treatment Research with Qu’s Novel Immunotherapy Platform
18 déc. 2020 13h00 HE | Qu Biologics, Inc.
VANCOUVER, British Columbia, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel...
Qu Biologics.png
Qu Biologics Completes $8M Financing
09 déc. 2020 06h00 HE | Qu Biologics, Inc.
VANCOUVER, British Columbia, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel...
BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia Issued New Patent for Delivery of Cardiac Cell Therapy Through Wrist Artery
29 sept. 2020 08h00 HE | BioCardia, Inc.
SAN CARLOS, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today...
logo.jpg
Codexis and Molecular Assemblies Partner to Transform the Field of DNA Synthesis
23 juin 2020 07h00 HE | Codexis, Inc.
REDWOOD CITY, Calif. and SAN DIEGO, June 23, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, and Molecular...
CDXS Elects New Independent Directors
Codexis Announces the Election of New Directors at its Annual Meeting of Stockholders
16 juin 2020 16h05 HE | Codexis, Inc.
REDWOOD CITY, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, announces the election of new...